Deepinder Dhaliwal, MD
Ophthalmology · Pittsburgh, PANPI 1588637094
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.7%), speaking fees and grants — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.2%. Reporting peaked in 2024 at $21,934 and has fallen 79.8% since, to $4,436 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $601.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$12K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Bausch & Lomb Americas Inc.$10K
- Novartis$9K
- Ocular Therapeutix, Inc.$5K
- Tarsus Pharmaceuticals, Inc.$5K
- plus $14K from 12 others
Across 33 payments — averaging $3184.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$44K
- Coopervision Inc.$20K
- Avedro Inc.$15K
- Novartis$9K
- Glaukos Corporation$8K
- Sight Sciences, Inc.$7K
- plus $1K from 1 others
What the payments were for
- Consulting fees$36,80457%
- Speaking & faculty fees$10,31516%
- Grants$10,00015%
- Travel & lodging$2,5824%
- Food & beverage$5,2598%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 24 | $11,827 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $10,091 |
| Bausch & Lomb Americas Inc. | 12 | $9,709 |
| Novartis | 12 | $9,377 |
| Ocular Therapeutix, Inc. | 3 | $5,211 |
| Tarsus Pharmaceuticals, Inc. | 7 | $4,969 |
| Merck | 8 | $3,209 |
| Shire North American Group Inc | 1 | $3,000 |
| Amgen(2 entities) | 3 | $2,590 |
| AbbVie(2 entities) | 12 | $1,868 |
| Oyster Point Pharma, Inc. | 2 | $855 |
| Lensar, Inc. | 2 | $715 |
| Dompe US, Inc. | 8 | $649 |
| Sun Pharmaceutical Industries Inc. | 6 | $543 |
| Alcon | 1 | $132 |
| Eyepoint US, Inc. | 2 | $108 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Glaukos Corporation | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STAR S4 IR$8,775
- TENEO$6,205
- DEXTENZA$5,200
- XIIDRA$4,094
- TEPEZZA$2,500
- CATALYS SYSTEM$1,935
- Tecnis IOL$1,792
- MIEBO$1,594
- XDEMVY$1,460
- RESTASIS$1,150
- VERITAS Vision System$1,025
- Tecnis Simplicity$895
- TYRVAYA$855
- LENSAR LASER SYSTEM$715
- CEQUA$484
- Oxervate$374
- IFS ADVANCED FEMTOSEC LASER$338
- XELPROS$252
- BROMSITE$252
- ReSTOR$132
How this compares
$64,960 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $59,076 |
| XiidraLifitegrast | 35 | $42,430 |
| Cyclosporine | 64 | $37,230 |
| XdemvyLotilaner | 15 | $26,577 |
| Fluorometholone | 272 | $24,168 |
| Prednisolone Acetate | 181 | $9,165 |
| Restasis MultidoseCyclosporine | 11 | $6,786 |
| FlarexFluorometholone Acetate | 39 | $4,988 |
| ValacyclovirValacyclovir Hcl | 59 | $2,604 |
| MoxifloxacinMoxifloxacin Hcl | 71 | $1,188 |
| Brimonidine Tartrate | 24 | $423 |
| Ketorolac Tromethamine | 13 | $326 |
| Latanoprost | 13 | $213 |
| Timolol Maleate | 26 | $126 |
| Dorzolamide Hcl | 11 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $1,868 | $65,86164 claims |
| Bausch & Lomb Americas Inc.Xiidra | $9,709 | $42,43035 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $4,969 | $26,57715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.1M
- Robert NoeckerPittsburgh$632K
- Srinivas KondapalliPittsburgh$208K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$82K
- Thomas FribergPittsburgh$55K
- Jenny YuPittsburgh$47K
- Vishal JhanjiPittsburgh$38K
- Omar AbbasiPittsburgh$36K
- Julia HallerPhiladelphia$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.